Multicenter Canaloplasty Data Registry – Outcomes Of Ab-Interno Canaloplasty Across Different Glaucoma Types And Severities

Collating results from the iTrack Global Data Registry (iTGDR), this study aims to investigate the efficacy and safety of ab-interno canaloplasty in reducing IOP and number of medications across all grades of glaucoma severity and types of glaucoma.

Prospective multicenter cloud-based database (IGSR), real-world study

Prospective multicenter cloud-based database (iTGDR, part of the International Glaucoma Surgery Registry – IGSR), real-world study including glaucoma patients undergoing canaloplasty with the iTrack or iTrack Advance device (Nova Eye Inc., Fremont, USA). Mean reduction in IOP and number of medications (meds) were the primary endpoints and eyes were grouped based on baseline glaucoma severity (early: better than -6dB; moderate: -6dB to -12dB; severe: worse than -12 dB), and glaucoma type.

257 eyes were enrolled up to November 2024. Postop data was taken from last observation (mean follow-up: 21.8±8 months). IOP and meds for open angle glaucoma (OAG) at preop vs postop: 17.0±5.1 vs 14.0±3.7 (n=218; -17.6%, p<0.001) and 2.2±1.2 vs 1.4±1.5 (-36.0%, p<0.001); for secondary OAG: 18.5±5.5 vs 14.4±5.9 (n=19; -21.9%, p<0.001) and 1.6±0.9 vs 0.7±1.1 (-56.7%, p=0.002); for ocular hypertension: 21.1±7.6 vs 16.8±4.3 (n=17; -20.3%, p=0.002) and 1.4±0.9 vs 0.5±1.1 (-66.7%, p<0.001). IOP for early, moderate, and severe groups at preop was 17.4±4.8 (n=145), 17.1±5.4 (n=55), 15.5±4.1 (n=35); at postop 14.3±3.8 (-17.5%, p<0.001), 14.5±3.7 (-15.4%, p<0.001), 13.0±4.7 (-16.5%, p=0.006) respectively.

Canaloplasty via an ab-interno technique was able to effectively reduce IOP and medication use across all types and stages of glaucoma.